Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Account Payables: 2016-2025

Historic Change in Account Payables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 10 years, with Sep 2025 value amounting to $1.5 million.

  • Viridian Therapeutics, Inc.\DE's Change in Account Payables fell 47.24% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 72.19%. This contributed to the annual value of -$73,000 for FY2024, which is 99.39% up from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Change in Account Payables is $1.5 million, which was down 66.62% from $4.6 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Change in Account Payables registered a high of $8.0 million during Q3 2022, and its lowest value of -$6.6 million during Q1 2023.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Change in Account Payables value was $438,000 (recorded in 2024), while the average stood at -$379,182.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Change in Account Payables tumbled by 21,541.94% in 2023 and then skyrocketed by 2,812.96% in 2024.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Change in Account Payables (Quarterly) stood at -$1.4 million in 2021, then spiked by 224.11% to $1.7 million in 2022, then crashed by 186.88% to -$1.5 million in 2023, then crashed by 158.77% to -$3.9 million in 2024, then slumped by 47.24% to $1.5 million in 2025.
  • Its Change in Account Payables stands at $1.5 million for Q3 2025, versus $4.6 million for Q2 2025 and $1.8 million for Q1 2025.